Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biomark Diagnostics Inc (BUX.CN)

Biomark Diagnostics Inc (BUX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 27,266
  • Shares Outstanding, K 90,886
  • Annual Sales, $ 153 K
  • Annual Income, $ -1,842 K
  • 60-Month Beta -1.36
  • Price/Sales 158.19
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BUX.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $-0.02 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Diagnostics & Research

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2400 +27.08%
on 04/18/24
0.3150 -3.17%
on 04/23/24
-0.0050 (-1.61%)
since 03/25/24
3-Month
0.2400 +27.08%
on 04/18/24
0.3150 -3.17%
on 04/23/24
+0.0250 (+8.93%)
since 01/25/24
52-Week
0.1700 +79.41%
on 08/03/23
0.3500 -12.86%
on 06/13/23
+0.0550 (+22.00%)
since 04/25/23

Most Recent Stories

More News
BioMark Announces Warrant Extension and Granting of Options

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark to Advance Development of Cancer Treatment for Glioblastoma

The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study.Vancouver, British Columbia--(Newsfile Corp. - April 9, 2024) - BioMark Diagnostics...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities

Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
Theresa Peterson Joins Biomark's Advisory Team

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced-stage liquid biopsy company with a focus on...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory developing...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

Dr. W. Randolph Ford, Ph.D., will be joining BioMark's Advisory team to support Artificial Intelligence and Machine Learning capabilities.Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023)...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company focusing...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium

Analyses from a retrospective study of early breast cancer metabolomics panel further demonstrate the diagnostic power of BioMark's liquid biopsy platform beyond early lung cancer detection.Vancouver,...

BMKDF : 0.2300 (+2.27%)
BUX.CN : 0.3050 (+1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research...

See More

Key Turning Points

3rd Resistance Point 0.3250
2nd Resistance Point 0.3150
1st Resistance Point 0.3100
Last Price 0.3050
1st Support Level 0.2950
2nd Support Level 0.2850
3rd Support Level 0.2800

See More

52-Week High 0.3500
Last Price 0.3050
Fibonacci 61.8% 0.2812
Fibonacci 50% 0.2600
Fibonacci 38.2% 0.2388
52-Week Low 0.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar